Broadwood Partners, L.P. Acquires 31,780 Shares of STAAR Surgical (NASDAQ:STAA) Stock

STAAR Surgical (NASDAQ:STAA) major shareholder Broadwood Partners, L.P. acquired 31,780 shares of the company’s stock in a transaction that occurred on Wednesday, April 2nd. The shares were acquired at an average cost of $17.43 per share, with a total value of $553,925.40. Following the purchase, the insider now owns 12,487,044 shares in the company, valued at $217,649,176.92. This represents a 0.26 % increase in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Large shareholders that own more than 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

Broadwood Partners, L.P. also recently made the following trade(s):

• On Monday, March 31st, Broadwood Partners, L.P. bought 22,189 shares of STAAR Surgical stock. The shares were bought at an average price of $17.46 per share, for a total transaction of $387,419.94.
• On Thursday, March 27th, Broadwood Partners, L.P. purchased 3,620 shares of STAAR Surgical stock. The stock was bought at an average cost of $17.48 per share, with a total value of $63,277.60.
• On Tuesday, March 25th, Broadwood Partners, L.P. acquired 34,296 shares of STAAR Surgical stock. The shares were bought at an average cost of $17.44 per share, for a total transaction of $598,122.24.
• On Thursday, March 20th, Broadwood Partners, L.P. bought 108,720 shares of STAAR Surgical stock. The stock was bought at an average cost of $17.96 per share, with a total value of $1,952,611.20.
• On Tuesday, March 18th, Broadwood Partners, L.P. purchased 93,124 shares of STAAR Surgical stock. The shares were purchased at an average cost of $17.54 per share, for a total transaction of $1,633,394.96.
• On Monday, March 3rd, Broadwood Partners, L.P. acquired 249,503 shares of STAAR Surgical stock. The shares were purchased at an average price of $16.64 per share, with a total value of $4,151,729.92.
• On Thursday, February 27th, Broadwood Partners, L.P. bought 259,316 shares of STAAR Surgical stock. The stock was purchased at an average price of $17.05 per share, for a total transaction of $4,421,337.80.
• On Friday, February 14th, Broadwood Partners, L.P. purchased 36,532 shares of STAAR Surgical stock. The shares were purchased at an average price of $15.49 per share, with a total value of $565,880.68.
• On Wednesday, February 12th, Broadwood Partners, L.P. acquired 259,616 shares of STAAR Surgical stock. The stock was acquired at an average price of $14.96 per share, with a total value of $3,883,855.36.
• On Thursday, January 16th, Broadwood Partners, L.P. purchased 8,221 shares of STAAR Surgical stock. The shares were acquired at an average price of $21.50 per share, with a total value of $176,751.50.

STAAR Surgical Stock Performance

STAA stock opened at $17.60 on Thursday. STAAR Surgical has a fifty-two week low of $13.50 and a fifty-two week high of $52.68. The company’s 50 day moving average price is $19.12 and its 200 day moving average price is $24.92. The firm has a market capitalization of $868.12 million, a price-to-earnings ratio of -42.93 and a beta of 0.66.

Analyst Upgrades and Downgrades

STAA has been the subject of several research analyst reports. William Blair lowered shares of STAAR Surgical from an “outperform” rating to a “market perform” rating in a research note on Wednesday, February 12th. StockNews.com downgraded shares of STAAR Surgical from a “hold” rating to a “sell” rating in a report on Thursday, February 13th. Piper Sandler cut their target price on STAAR Surgical from $40.00 to $16.00 and set a “neutral” rating on the stock in a research report on Wednesday, February 12th. Canaccord Genuity Group lowered their price target on STAAR Surgical from $28.00 to $17.00 and set a “hold” rating for the company in a research report on Thursday, February 13th. Finally, Stifel Nicolaus cut their price objective on STAAR Surgical from $38.00 to $20.00 and set a “buy” rating on the stock in a report on Wednesday, February 12th. Two investment analysts have rated the stock with a sell rating, eight have given a hold rating and one has assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, STAAR Surgical presently has an average rating of “Hold” and a consensus price target of $25.29.

Hedge Funds Weigh In On STAAR Surgical

A number of institutional investors and hedge funds have recently modified their holdings of the company. Quarry LP acquired a new stake in STAAR Surgical in the third quarter valued at $50,000. FMR LLC raised its position in shares of STAAR Surgical by 79.3% during the 3rd quarter. FMR LLC now owns 7,092 shares of the medical instruments supplier’s stock worth $263,000 after acquiring an additional 3,136 shares in the last quarter. KLP Kapitalforvaltning AS acquired a new stake in shares of STAAR Surgical during the 4th quarter worth about $180,000. HighTower Advisors LLC purchased a new stake in STAAR Surgical during the third quarter worth approximately $336,000. Finally, Bridgefront Capital LLC boosted its holdings in STAAR Surgical by 27.2% in the fourth quarter. Bridgefront Capital LLC now owns 10,792 shares of the medical instruments supplier’s stock valued at $262,000 after purchasing an additional 2,306 shares in the last quarter. Institutional investors and hedge funds own 96.70% of the company’s stock.

About STAAR Surgical

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia.